Cannabics Pharmaceuticals Inc. issued the following announcement on Nov. 9.
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based therapeutic formulations and medicines, announced today that it has completed a pre-clinical study using its proprietary and novel RCC-33 formulation on human biopsies, obtained under a Helsinki Committee approved protocol. The results show an antitumor synergistic effect of the active compounds, thus confirming the company' previously obtained data on the antitumor properties of the drug candidate when screened on colorectal cell lines.
Dr. Eyal Ballan, Cannabics Pharmaceuticals' CTO said: "the study results brings us one step closer in preparing our submission to the U.S. Food and Drug Administration for a pre-IND meeting. Our next step will be launching a study on mice to try and demonstrate the same synergistic effect and see tumor growth attenuation in-vivo."
About Cannabics Pharmaceuticals
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a U.S. public company and a global leader in the development of cancer related cannabinoid-based therapeutic formulations and medicines. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer. For more information, please visit www.cannabics.com. For the latest updates on Cannabics Pharmaceuticals follow the Company on Twitter @Cannabics, Facebook @CannabicsPharmaceuticals, LinkedIn, and on Instagram @Cannabics_Pharmaceuticals.
Original source can be found here.
